9CUAB30

DB12316InvestigationalSmall molecule

9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among others.

Mechanism: Pharmacologically active on Human Retinoid X Receptors (RXRs)
Curator reviewed
Formula / weight: C₂₀H₂₂O₂ · 294.3875 g/mol (avg)
Also known as: RETINOID 9CUAB30
Code names: 9CUAB30

Resolves to

Compound

UNIIPFP09575EXCAS205252-57-9ChEMBLCHEMBL3098771PubChem9904203

Structure

InChIKeyPPGNMFUMZSAZCW-VOYUZAMQSA-NSMILES[H]/C(=C(/[H])\C(\C)=C(/[H])C(O)=O)/C(/[H])=C(/C)\C(\[H])=C1/CCCC2=CC=CC=C12

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of 9CUAB30, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account